Slowed down? New antidiabetics in Germany
Diabetes mellitus often has serious and long-term consequences for those affected, both in terms of health and economics. It's not just the medically complex complications of the metabolic disease that affect the quality of life of patients. Drug therapy, which is usually necessary for life, also requires a high level of long-term adherence on the part of the patient. In addition, the approval of new active ingredients always raises the question of whether existing therapy needs to be reviewed and possibly adjusted. The present analysis shows new developments in the antidiabetics market and compares innovative and existing drugs, also taking the AMNOG (Medicines Market Reorganization Act) into account.
Read more
First publication date: 16.10.2014
Downloads
Additional Information
- Issue: Issue 06/2014 Publication Date: 16.10.2014 All issues as PDF Subscribe to print magazine Order single issue Open Access
